Answers are grounded in this paper and cite their sources.
Combined therapy with ACE inhibitors and spironolactone in heart failure requires careful patient selection, low initial dosing, and close monitoring of serum potassium and renal function to prevent severe hyperkalaemia.
Since the publication of The Randomized Aldactone Study (RALES) in 1999, the association of angiotensin-converting enzyme (ACE) inhibitors and spironolactone has been largely used for the treatment of congestive heart failure (CHF). Although this study had shown a diminished morbimortality in patients with CHF that are treated with spironolactone and ACE inhibitors and a low risk (2%) of development of severe hyperkalaemia, other clinical studies have shown higher rates of hyperkalaemia and serious adverse clinical events culminating in death. Therefore, the identification of risk factors for the development of hyperkalaemia in CHF patients, close monitoring of serum potassium and determination of renal function before and after the initiation of combined therapy or after a dose increment, should be routinely performed. It is strongly recommended that these drugs be initiated in low doses and that the increment in dose should only occur after considering all safety issues.
No takes yet. Share an insight, caveat, or question.
Cruz et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: